Literature DB >> 20386428

Discordance between CD4 cell count and CD4 cell percentage: implications for when to start antiretroviral therapy in HIV-1 infected children.

K Boyd, David T Dunn, H Castro, D M Gibb, T Duong, J P Aboulker, M Bulterys, M Cortina-Borja, C Gabiano, L Galli, C Giaquinto, D R Harris, M HugheS, R McKinney, L Mofenson, J Moye, M L Newell, S Pahwa, P Palumbo, C Rudin, M Sharland, W Shearer, B Thompson, P Tookey.   

Abstract

OBJECTIVE: Antiretroviral therapy (ART) guidelines for HIV-1-infected children specify both absolute CD4 cell count and CD4 percentage thresholds at which consideration should be given to initiating ART. This leads to clinical dilemma when one marker is below the threshold, whereas the other is above.
DESIGN: Data were obtained on a large group of children followed longitudinally in trials and cohort studies in Europe and the USA. Follow-up was censored 6 months after the start of any antiretroviral drug other than zidovudine monotherapy.
METHODS: Discordance between CD4 cell count and percentage was defined in relation to ART initiation thresholds in World Health Organization (WHO) and European paediatric treatment guidelines. The relative prognostic value of CD4 cell count and percentage for progression to AIDS/death was investigated using time-updated Cox proportional hazards models, stratified by age.
RESULTS: Among 3345 children, with a total of 21,815 pairs of CD4 measurements analysed, 980 developed AIDS and/or died after a median follow-up of 1.7 years. Over one-half of children had discordant values of CD4 cell markers at the first visit when one or both treatment thresholds were crossed and approximately one-third had the same pattern of discordance at a subsequent measurement. Models suggested that CD4 percentage had little or no prognostic value over and above that contained in CD4 cell count, irrespective of age.
CONCLUSIONS: More emphasis should be placed on CD4 cell count than on CD4 percentage in deciding when to start ART in HIV-1-infected children.

Entities:  

Mesh:

Year:  2010        PMID: 20386428     DOI: 10.1097/QAD.0b013e3283389f41

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  12 in total

1.  Mortality in Children with Human Immunodeficiency Virus Initiating Treatment: A Six-Cohort Study in Latin America.

Authors:  Marco T Luque; Cathy A Jenkins; Bryan E Shepherd; Denis Padgett; Vanessa Rouzier; Regina Célia M Succi; Daisy M Machado; Catherine C McGowan; Sten H Vermund; Jorge A Pinto
Journal:  J Pediatr       Date:  2017-01-09       Impact factor: 4.406

2.  Paediatric European Network for Treatment of AIDS (PENTA) guidelines for treatment of paediatric HIV-1 infection 2015: optimizing health in preparation for adult life.

Authors:  A Bamford; A Turkova; H Lyall; C Foster; N Klein; D Bastiaans; D Burger; S Bernadi; K Butler; E Chiappini; P Clayden; M Della Negra; V Giacomet; C Giaquinto; D Gibb; L Galli; M Hainaut; M Koros; L Marques; E Nastouli; T Niehues; A Noguera-Julian; P Rojo; C Rudin; H J Scherpbier; G Tudor-Williams; S B Welch
Journal:  HIV Med       Date:  2015-02-03       Impact factor: 3.180

3.  Predictors of loss to follow-up after engagement in care of HIV-infected children ineligible for antiretroviral therapy in an HIV cohort study in India.

Authors:  Gerardo Alvarez-Uria; Praveen Kumar Naik; Manoranjan Midde; Raghavakalyan Pakam
Journal:  Germs       Date:  2014-03-03

4.  Early antiretroviral treatment reduces risk of bacille Calmette-Guérin immune reconstitution adenitis.

Authors:  H Rabie; A Violari; T Duong; S A Madhi; D Josipovic; S Innes; E Dobbels; E Lazarus; R Panchia; A G Babiker; D M Gibb; M F Cotton
Journal:  Int J Tuberc Lung Dis       Date:  2011-09       Impact factor: 2.373

5.  Association between age at antiretroviral therapy initiation and 24-month immune response in West-African HIV-infected children.

Authors:  Sophie Desmonde; Fatoumata Dicko; Fla Koueta; Tanoh Eboua; Eric Balestre; Clarisse Amani-Bosse; Edmond A Aka; Koko Lawson-Evi; Madeleine Amorissani-Folquet; Kouadio Kouakou; Siriatou Koumakpai; Lorna Renner; Haby Signaté Sy; Valériane Leroy
Journal:  AIDS       Date:  2014-07-17       Impact factor: 4.177

6.  Mortality in the year following antiretroviral therapy initiation in HIV-infected adults and children in Uganda and Zimbabwe.

Authors:  A Sarah Walker; Andrew J Prendergast; Peter Mugyenyi; Paula Munderi; James Hakim; Addy Kekitiinwa; Elly Katabira; Charles F Gilks; Cissy Kityo; Patricia Nahirya-Ntege; Kusum Nathoo; Diana M Gibb
Journal:  Clin Infect Dis       Date:  2012-09-12       Impact factor: 9.079

7.  Predicting patterns of long-term CD4 reconstitution in HIV-infected children starting antiretroviral therapy in sub-Saharan Africa: a cohort-based modelling study.

Authors:  Marie-Quitterie Picat; Joanna Lewis; Victor Musiime; Andrew Prendergast; Kusum Nathoo; Addy Kekitiinwa; Patricia Nahirya Ntege; Diana M Gibb; Rodolphe Thiebaut; A Sarah Walker; Nigel Klein; Robin Callard
Journal:  PLoS Med       Date:  2013-10-29       Impact factor: 11.069

8.  Description of the cascade of care and factors associated with attrition before and after initiating antiretroviral therapy of HIV infected children in a cohort study in India.

Authors:  Gerardo Alvarez-Uria
Journal:  PeerJ       Date:  2014-03-13       Impact factor: 2.984

9.  Separating signal from noise: the challenge of identifying useful biomarkers in sepsis.

Authors:  Russell J McCulloh; John A Spertus
Journal:  Crit Care       Date:  2014-03-17       Impact factor: 9.097

10.  Mortality and Loss to Follow up Before Initiation of Antiretroviral Therapy Among HIV-Infected Children Eligible for HIV Treatment.

Authors:  Gerardo Alvarez-Uria; Praveen Kumar Naik; Manoranjan Midde; Raghavakalyan Pakam
Journal:  Infect Dis Rep       Date:  2014-05-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.